The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas Velcade as a retreatment for multiply relapsed patients who previously responded well to it, will no longer be available via the CDF. The announcements are a result of recent reforms that have meant that drugs on the list were reassessed on the basis of clinical and cost-effectiveness. Changes are expected to be implemented in the next two months.


Read full article